News
AMTI
1.960
+0.51%
0.010
When Can We Expect A Profit From Applied Molecular Transport Inc. (NASDAQ:AMTI)?
With the business potentially at an important milestone, we thought we'd take a closer look at Applied Molecular...
Simply Wall St. · 4d ago
Applied Molecular Transport GAAP EPS of -$0.93
Applied Molecular Transport press release (<span cl...
Seekingalpha · 08/04 21:41
--Jefferies Downgrades Applied Molecular Transport to Hold From Buy
MT Newswires · 07/07 05:16
Dow Jumps More Than 100 Points Following Release Of Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the recent Federal Reserve meeting, which suggest inflation remains the central bank's top priority. The country's central bank reiterated its prior intentions to do...
Benzinga · 07/06 19:00
U.S. Stocks Turn Lower; Amazon Acquires This Much Stake in Grubhub
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 150 points on Wednesday. Investors are awaiting minutes from the recent Federal Reserve meeting.
Benzinga · 07/06 17:46
BRIEF-Applied Molecular Transport Announces Top-Line Phase 2 Results From Market Combination Trial Of Oral AMT-101
BRIEF-Applied Molecular Transport Announces Top-Line Phase 2 Results From Market Combination Trial Of Oral AMT-101
Reuters · 07/06 12:45
DoorDash, SOS, Kornit Digital among premarket losers' pack
Applied Molecular Transport (AMTI) -40% <a href="https://seekinga...
Seekingalpha · 07/06 12:19
Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week
Benzinga · 07/06 12:05
Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data
Shares of Applied Molecular Transport (NASDAQ:AMTI</spa...
Seekingalpha · 07/05 20:37
Applied Molecular Transport To Report Top-Line Phase 2 Results From Market Combination Trial Of Oral AMT-101 In Patients With Moderate-To-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with
Benzinga · 07/05 20:02
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report...
GlobeNewswire · 07/05 20:01
Applied Molecular to Report Ulcerative Colitis Trial Results Wednesday -- Stock Up 4% After-Hours
MT Newswires · 07/05 17:08
Insiders might want to re-evaluate their US$1.2m stock purchase as Applied Molecular Transport Inc. (NASDAQ:AMTI) drops to US$112m
The recent 21% drop in Applied Molecular Transport Inc.'s ( NASDAQ:AMTI ) stock could come as a blow to insiders who...
Simply Wall St. · 07/03 13:50
Applied Molecular Transport to Present at Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences: Eve...
GlobeNewswire · 06/02 12:00
44 Stocks Moving In Wednesday's Mid-Day Session
Gainers
Benzinga · 06/01 16:14
10 Biggest Price Target Changes For Friday
Telsey Advisory Group lowered the price target for Best Buy Co., Inc. (NYSE: BBY) from $130 to $90. Best Buy shares rose 0.4% to $73.58 in pre-market trading.
Benzinga · 05/20 12:04
--SVB Securities Adjusts Price Target on Applied Molecular Transport to $21 From $60, Keeps Outperform Rating
MT Newswires · 05/20 05:58
JMP Securities Adjusts Price Target on Applied Molecular Transport to $50 From $86, Maintains Market Outperform Rating
MT Newswires · 05/19 07:44
Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs
Benzinga · 05/18 16:41
Applied Molecular to prioritize resources on lead clinical programs, reduce workforce
Applied Molecular Transport (NASDAQ:AMTI) stock has lost 5.2% to $4.05 in Wednesday morning trade, after the clinical-stage biopharmaceutical company said it would prioritize its resources on its lead clinical programs, reduce its
Seekingalpha · 05/18 14:09
More
Webull provides a variety of real-time AMTI stock news. You can receive the latest news about Applied Molecular Transport Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform, including AMT-101, an oral gastrointestinal (GI)-selective oral fusion of interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of interleukin 22 (IL-22). Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.